|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 781.20 EGP | +5.55% |
|
+4.62% | +123.71% |
| 06-10 | MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 05-05 | Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million | RE |
Company Valuation: MINAPHARM Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 987 | 1,303 | 1,822 | 2,408 | 1,796 | 4,114 |
| Change | - | 32.02% | 39.82% | 32.19% | -25.41% | 129.01% |
| Enterprise Value (EV) 1 | 922 | 1,570 | 2,562 | 4,297 | 4,395 | 5,224 |
| Change | - | 70.23% | 63.21% | 67.74% | 2.27% | 18.88% |
| P/E | 3.28x | 2.91x | 2.88x | -43.5x | 14x | 584x |
| PBR | 0.64x | 0.69x | 0.55x | 0.7x | 0.44x | 0.66x |
| PEG | - | 0.1x | 0.1x | 0x | -0x | -6.2x |
| Capitalization / Revenue | 0.42x | 0.43x | 0.5x | 0.62x | 0.32x | 0.64x |
| EV / Revenue | 0.39x | 0.52x | 0.71x | 1.1x | 0.78x | 0.81x |
| EV / EBITDA | 1.48x | 1.89x | 2.36x | 8.02x | 3.75x | 3.87x |
| EV / EBIT | 1.71x | 2.1x | 2.66x | 11.5x | 4.71x | 5.13x |
| EV / FCF | 3.33x | -10.9x | -4.11x | -3.25x | -10.3x | -28.5x |
| FCF Yield | 30.1% | -9.18% | -24.3% | -30.7% | -9.71% | -3.51% |
| Dividend per Share 2 | 2.7 | 2.922 | 2.8 | 1.65 | 2.5 | - |
| Rate of return | 3.36% | 2.76% | 1.89% | 0.76% | 1.54% | - |
| EPS 2 | 24.47 | 36.42 | 51.41 | -5.006 | 11.58 | 0.5979 |
| Distribution rate | 11% | 8.02% | 5.45% | -33% | 21.6% | - |
| Net sales 1 | 2,361 | 3,005 | 3,621 | 3,892 | 5,665 | 6,438 |
| EBITDA 1 | 621.7 | 828.5 | 1,086 | 536 | 1,172 | 1,348 |
| EBIT 1 | 538.8 | 746.5 | 964.7 | 374.7 | 933.8 | 1,019 |
| Net income 1 | 300.8 | 466.4 | 612.7 | -31.99 | 157.1 | 40.22 |
| Net Debt 1 | -65.01 | 266.5 | 739.6 | 1,889 | 2,598 | 1,110 |
| Reference price 2 | 80.29 | 106.00 | 148.21 | 217.68 | 162.36 | 349.20 |
| Nbr of stocks (in thousands) | 12,293 | 12,293 | 12,293 | 11,064 | 11,064 | 11,781 |
| Announcement Date | 3/31/21 | 3/31/22 | 3/30/23 | 4/7/24 | 6/12/25 | 6/10/26 |
1EGP in Million2EGP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 170M | |
| 36.37x | 6.89x | 23.79x | 0.86% | 50.03B | |
| 17.89x | 2.07x | 9.57x | 1.4% | 36.6B | |
| 28.68x | 3.5x | 18.13x | 0.87% | 12.47B | |
| 26.71x | 3.94x | 16.04x | 0.59% | 11.77B | |
| 19x | 3.32x | 11.92x | 3.5% | 9.04B | |
| 15.69x | 2.02x | 6.33x | 3.29% | 7.03B | |
| 8.24x | 1.93x | 5.06x | 5.26% | 6.79B | |
| 33.91x | 3.86x | 16.43x | 0.24% | 6.6B | |
| Average | 23.31x | 3.44x | 13.41x | 2% | 15.61B | |
| Weighted average by Cap. | 26.43x | 4.23x | 16.04x | 1.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MIPH Stock
- Valuation MINAPHARM Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
